A novel chimeric protein composed of recombinant Mycoplasma hyopneumoniae antigens as a vaccine candidate evaluated in mice
A novel chimeric protein composed of recombinant Mycoplasma hyopneumoniae antigens as a vaccine candidate evaluated in mice
复制标题
DOI：
10.1016/j.vetmic.2017.01.023
复制
发表时间：
2017-03-01
影响因子：
3.3
通讯作者：
Dellagostin, Odir Antonio
中科院分区：
文献类型：
--
作者：
de Oliveira, Natasha Rodrigues;Jorge, Sergio;Dellagostin, Odir Antonio
地方性肺炎（EP）是由猪肺炎支原体（Mycoplasma hyoproteinuria）病原菌引起的，并且它代表了一种重要的呼吸道疾病，其在全世界的养猪业中造成重大经济损失。目前市售的抗真菌素已被证明仅提供针对M.因此，需要开发更有效的疫苗。已经通过不同的免疫策略评估了几种重组抗原，并且已经发现其具有高度免疫原性。本工作描述了由四个M组成的多抗原嵌合体的构建和免疫学特性。猪流感抗原：P97 R1、P46、P95和P42。选择每种抗原的免疫原性区域并组合以编码单一多肽。将该基因克隆并在大肠杆菌中表达，嵌合蛋白被针对每个亚基的特异性抗体识别，以及被恢复期猪血清识别。然后通过如下配制的两种重组疫苗在小鼠模型中评价嵌合体的免疫原性：（1）纯化的嵌合蛋白加佐剂或（2）重组大肠杆菌重组蛋白。在用每种制剂免疫的BALB/c小鼠中诱导的免疫应答根据针对嵌合体中存在的每种抗原的总IgG水平、IgGl和IgG 2a同种型来表征。研究结果表明，新的嵌合蛋白是未来开发更有效的EP疫苗的潜在候选者。(C)2017爱思唯尔B. V.保留所有权利。
Enzootic Pneumonia (EP) is caused by the Mycoplasma hyopneumoniae pathogenic bacteria, and it represents a significant respiratory disease that is responsible for major economic losses within the pig industry throughout the world. The bacterins that are currently commercially available have been proven to offer only partial protection against M. hyopneumoniae, and the development of more efficient vaccines is required. Several recombinant antigens have been evaluated via different immunization strategies and have been found to be highly immunogenic. This work describes the construction and immunological characterization of a multi-antigen chimera composed of four M. hyopneumoniae antigens: P97R1, P46, P95, and P42. Immunogenic regions of each antigen were selected and combined to encode a single polypeptide. The gene was cloned and expressed in Escherichia coil, and the chimeric protein was recognized by specific antibodies against each subunit, as well as by convalescent pig sera. The immunogenic properties of the chimera were then evaluated in a mice model through two recombinant vaccines that were formulated as follows: (1) purified chimeric protein plus adjuvant or (2) recombinant Escherichia coli bacterin. The immune response induced in BALB/c mice immunized with each formulation was characterized in terms of total IgG levels, IgGl, and IgG2a isotypes against each antigen present in the chimera. The results of the study indicated that novel chimeric protein is a potential candidate for the future development of a more effective vaccine against EP. (C) 2017 Elsevier B.V. All rights reserved.